The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
ALX Oncology To Initiate New Clinical Study ASPEN-07 In Q4
–Expansion of solid tumor clinical program
–ASPEN-02 dose optimization data to inform dosing for ASPEN-05
SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc.,
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 211 companies set new 52-week lows.
Stifel Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $36
Stifel analyst Bradley Canino maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $60 to $36.
ALX Oncology Granted Orphan Drug Designation For ‘Treatment for gastric cancer and gastro-esophageal junction cancer’
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=782220
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning session, 34 stocks hit new 52-week lows.